All In Biotech

Drug Trial Radar · NCT06188455

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Clinical Study of Fluzopalil Combined With Apatinib for Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

37

Planned (sponsor's estimate)

Start

Dec 1, 2024

Primary completion

Dec 1, 2025

Study completion Dec 1, 2026

Sponsor

Lead sponsor
The First Affiliated Hospital of Xiamen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled

Conditions

  • Ovarian Cancer

Interventions

  • Fluzoparib CapsulesDrug

    Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily

  • Apatinib Mesylate TabletsDrug

    Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: up to12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.